.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Daiichi Sankyo
Colorcon
UBS
Chinese Patent Office
Merck
McKesson
Fish and Richardson
Healthtrust
Citi

Generated: September 19, 2017

DrugPatentWatch Database Preview

Perrigo Pharma Intl Company Profile

« Back to Dashboard

What is the competitive landscape for PERRIGO PHARMA INTL, and what generic alternatives to PERRIGO PHARMA INTL drugs are available?

PERRIGO PHARMA INTL has thirteen approved drugs.

There are six US patents protecting PERRIGO PHARMA INTL drugs on PERRIGO PHARMA INTL drugs in the past three years.

There are eighty-five patent family members on PERRIGO PHARMA INTL drugs in twenty-three countries.

Summary for Applicant: Perrigo Pharma Intl

Patents:6
Tradenames:8
Ingredients:8
NDAs:13
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo Pharma Intl
TRETINOIN
tretinoin
GEL;TOPICAL075589-001Jun 11, 2002ABRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo Pharma Intl
TRETINOIN
tretinoin
CREAM;TOPICAL075213-001Dec 24, 1998ABRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo Pharma Intl
CLINDESSE
clindamycin phosphate
CREAM;VAGINAL050793-001Nov 30, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Perrigo Pharma Intl
TRETINOIN
tretinoin
CREAM;TOPICAL075265-001Dec 24, 1998AB1RXNoNo► Subscribe► Subscribe► Subscribe
Perrigo Pharma Intl
LORATADINE AND PSEUDOEPHEDRINE SULFATE
loratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL076050-001Jan 30, 2003OTCNoNo► Subscribe► Subscribe► Subscribe
Perrigo Pharma Intl
CLINDESSE
clindamycin phosphate
CREAM;VAGINAL050793-001Nov 30, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Perrigo Pharma Intl
TRETINOIN
tretinoin
GEL;TOPICAL075529-001Feb 22, 2000ABRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo Pharma Intl
LORATADINE AND PSEUDOEPHEDRINE SULFATE
loratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL075989-001Mar 4, 2004OTCNoNo► Subscribe► Subscribe► Subscribe
Perrigo Pharma Intl
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Perrigo Pharma Intl
ENTOCORT EC
budesonide
CAPSULE;ORAL021324-001Oct 2, 2001ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Perrigo Pharma Intl

Paragraph IV activity for PERRIGO PHARMA INTL drugs

Drugname Dosage Strength Tradename Submissiondate
clindamycin phosphate
Vaginal Cream2%
CLINDESSE
2/5/2015
budesonide
Enteric Coated Capsules3 mg
ENTOCORT EC
2/1/2008

Non-Orange Book Patents for Perrigo Pharma Intl

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,071,075Dermal penetration enhancers and drug delivery systems involving the same► Subscribe
6,416,778 Pharmaceutical preparations and methods for their regional administration► Subscribe
6,929,801 Transdermal delivery of antiparkinson agents► Subscribe
6,916,487 Transdermal delivery of antiemetics► Subscribe
6,916,486 Transdermal delivery of analgesics► Subscribe
7,438,203Dermal penetration enhancers and drug delivery systems involving same► Subscribe
7,094,422Topical delivery of antifungal agents► Subscribe
7,387,789Transdermal delivery of non-steroidal anti-inflammatory drugs► Subscribe
6,652,874 Pharmaceutical preparations and methods for their regional administration► Subscribe
6,998,138Topical delivery of anti-alopecia agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Perrigo Pharma Intl Drugs

Country Document Number Estimated Expiration
Denmark1769785► Subscribe
Canada2392473► Subscribe
European Patent Office1611878► Subscribe
Austria324865► Subscribe
Australia5922798► Subscribe
Australia1713497► Subscribe
Portugal977555► Subscribe
World Intellectual Property Organization (WIPO)9729735► Subscribe
Germany122012000021► Subscribe
South Korea20030076159► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Perrigo Pharma Intl Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009004Lithuania► SubscribePRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
C/GB08/005United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
C/GB09/026United Kingdom► SubscribePRODUCT NAME: ESTRADIOL AND COMBINATIONS OF ESTRADIOL AND DIENOGEST, PREFERABLY ESTRADIOL VALERATE AND COMBINATIONS OF ESTRADIOL VALERATE AND DIENOGEST; REGISTERED: BE BE 327792 20081103; UK PL 00010/0576-0001 20081208
2012 00011Denmark► Subscribe
00C/027Belgium► SubscribePRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
972Luxembourg► Subscribe91972, EXPIRES: 20220219
00522Netherlands► SubscribePRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
00617Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
2012 00010Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Colorcon
Baxter
UBS
Boehringer Ingelheim
US Department of Justice
Fuji
Chinese Patent Office
Daiichi Sankyo
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot